Intracavitary therapeutic options in the management of cystic craniopharyngioma

Cáceres, Adrián

doi:10.1007/s00381-005-1227-0

Cited by 71 publications

(51 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no consensus in the literature on the best way to treat an adamantinomatous craniopharyngioma in childhood. Intratumoral chemotherapy with bleomycin or the intracystic application of radiopharmacological agents may control these tumors, but numerous side effects have been described 5 …”

Section: Introductionmentioning

confidence: 99%

Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon

Dastoli

Nicácio

Silva

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objective: To assess whether the cystic craniopharyngiomas can be controlled with the use of intratumoral applications of interferon alpha. Method: Nineteen patients with the diagnosis of cystic craniopharyngioma were treated with intratumoral chemotherapy with interferon alpha from January 2002 to April 2006. All patients underwent placement of an intracystic catheter connected to an Ommaya reservoir. Through this reservoir were made applications during chemotherapy cycles. Each cycle corresponded to application of 3,000,000 units of interferon alpha three times per week on alternate days totalizing 36,000,000 units. Response to treatment was evaluated by calculating the tumor volume on MRI control after one, three and six months after the end of each cycle. Patients who developed worsening of symptoms or who had insignificant reduction in tumor volume during follow-up underwent repeat cycle chemotherapy. Results: Four patients received four cycles of chemotherapy, three patients received three cycles, six patients received two cycles and six patients received one. The lower percentage of reduction in tumor volume was 60% and the bigger reduction was 98.37%. Eleven patients had a reduction greater than 90%. Five patients had a tumor reduction between 75 and 90% and in three patients the tumors were reduced by less than 75%. No deaths occurred during treatment and side effects of interferon alpha were well tolerated. No treatment was discontinued. Follow-up after the last application ranged from one year and five months to three years and nine months. Conclusion: The intratumoral chemotherapy with interferon alpha decreases the volume of cystic craniopharyngiomas and so far can be considered a new therapeutic alternative.

show abstract

Section: Introductionmentioning

confidence: 99%

Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon

Dastoli

Nicácio

Silva

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…The safety and efficacy of such an approach was recently documented in three cases by Mori et al in which no complications occurred with placement of Ommaya reservoir catheters over the outer surface of a transparent endoscopic sheath [122]. Given that 90 % of craniopharyngiomas are reported to have a cystic component, such a technique provides an effective approach in lesion management [123].…”

Section: Intraventricular Cystsmentioning

confidence: 99%

Ventricular endoscopy in the pediatric population: review of indications

et al. 2014

View full text Add to dashboard Cite

Introduction Neuroendoscopy has greatly impacted pediatric neurosurgery over the past few decades. Improved optics and microsurgical tools have allowed neuroendoscopes to be used for a multitude of neurosurgical procedures. Discussion In this review article, we present the breadth of intraventricular neuroendoscopic procedures for the treatment of conditions ranging from hydrocephalus and brain tumors to congenital cysts and other pathologies. We critically discuss treatment indications and reported success rates for neuroendoscopic procedures. We also present novel approaches, technical nuances, and variations from recently published literature and as practiced in the authors' institution.

show abstract

“…Regardless of the beta-emitting radionuclide used, intracavitary radiotherapy reduces the size of the cyst in 50 to 100% of cases, according to different case series. 6,23 Patient survival at 10 years after this treatment is also good, ranging from 45 to 80%. 6 However, in the longest followed series of patients reported, survival continued to decline over time, falling to < 20% after 20 years and 0% by 30 years.…”

mentioning

confidence: 95%

“…6,23 Patient survival at 10 years after this treatment is also good, ranging from 45 to 80%. 6 However, in the longest followed series of patients reported, survival continued to decline over time, falling to < 20% after 20 years and 0% by 30 years. 23 New endocrinopathy is very unusual after intracystic radiotherapy, but visual loss and radionecrosis of the hypothalamic or pontomesencephalic regions have been noted in approximately 5% of patients, and vascular involvement with moyamoya disease or subarachnoid hemorrhage more rarely.…”

mentioning

confidence: 95%

“…23 New endocrinopathy is very unusual after intracystic radiotherapy, but visual loss and radionecrosis of the hypothalamic or pontomesencephalic regions have been noted in approximately 5% of patients, and vascular involvement with moyamoya disease or subarachnoid hemorrhage more rarely. 6,23 One of the negatives of intracavitary radiotherapy is the small number of facilities with access to the radioisotopes and the complexity of the process for instillation of such materials into the cyst.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Intracystic treatments for craniopharyngioma

Steinbok¹,

Hukin

2010

FOC

View full text Add to dashboard Cite

Craniopharyngioma is a benign tumor histopathologically and in theory should be curable by radical resection. In practice, this tumor behaves like a chronic disease, with many issues related to the effect of the tumor itself and the various treatments on the adjacent structures, such as the pituitary stalk and gland, hypothalamus, visual apparatus, and suprasellar arteries. A multimodality approach to the management of these tumors may produce the optimal outcome, balancing disease control and quality of life. In this paper, the role of intracystic therapies is reviewed, with the major focus on intracystic bleomycin and interferon-α.

show abstract

Intracavitary therapeutic options in the management of cystic craniopharyngioma

Abstract: Overall, these newer options stand out as valid alternatives in the controversial management of these challenging tumors.

Cited by 71 publications

References 59 publications

Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon

Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon

Ventricular endoscopy in the pediatric population: review of indications

Intracystic treatments for craniopharyngioma

Contact Info

Product

Resources

About